StockData
Biodesix Inc logo

Biodesix Inc (BDSX) stock

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$8.40−0.48 (-5.41%)

Close on Nov 18, 2026Market cap $88.63MP/E –Yield –

Biodesix free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Biodesix's free cash flow for the twelve months ending Jun 30, 2026 was -$20.24M. For fiscal 2025 it was -$23.53M. The highest annual figure on record is -$23.04M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$23.53M–
FY2024Dec 31, 2024-$51.88M–
FY2023Dec 31, 2023-$45.79M–
FY2022Dec 31, 2022-$48.27M–
FY2021Dec 31, 2021-$30.46M–
FY2020Dec 31, 2020-$23.31M–
FY2019Dec 31, 2019-$23.04M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.76M–
Q1 FY2026Mar 31, 2026-$10.25M–
Q4 FY2025Dec 31, 2025$692.00K–
Q3 FY2025Sep 30, 2025-$8.93M–
Q2 FY2025Jun 30, 2025-$6.62M–
Q1 FY2025Mar 31, 2025-$8.68M–
Q4 FY2024Dec 31, 2024-$4.94M–
Q3 FY2024Sep 30, 2024-$10.90M–
Q2 FY2024Jun 30, 2024-$20.50M–
Q1 FY2024Mar 31, 2024-$15.55M–
Q4 FY2023Dec 31, 2023-$15.27M–
Q3 FY2023Sep 30, 2023-$9.68M–
Q2 FY2023Jun 30, 2023-$5.48M–
Q1 FY2023Mar 31, 2023-$15.36M–
Q4 FY2022Dec 31, 2022-$13.88M–
Q3 FY2022Sep 30, 2022-$11.11M–
Q2 FY2022Jun 30, 2022-$9.92M-1326.6%
Q1 FY2022Mar 31, 2022-$13.36M–
Q4 FY2021Dec 31, 2021-$10.73M–
Q3 FY2021Sep 30, 2021-$8.75M–
Q2 FY2021Jun 30, 2021$809.00K–
Q1 FY2021Mar 31, 2021-$11.79M–
Q4 FY2020Dec 31, 2020-$9.22M–
Q3 FY2020Sep 30, 2020-$5.02M–
Q2 FY2020Jun 30, 2020-$4.44M–
Q1 FY2020Mar 31, 2020-$4.64M–
Q4 FY2019Dec 31, 2019-$6.12M–

More Biodesix figures

See a number that looks wrong?